Target intelligence / Profile preview

Lactose operon repressor (LacI) (LacI)

Target
LacI
Molecular classification
Transcription factor, DNA-binding protein, Repressor protein
01

Overview

The Lactose operon repressor (LacI) is a well-characterized transcription factor from Escherichia coli that serves as the fundamental model for understanding gene regulation and allosteric control [1, 3, 12]. It functions by binding to specific operator DNA sequences to block the expression of genes involved in lactose utilization when the sugar is absent. In the presence of lactose-derived inducers like allolactose, the repressor undergoes a conformational change that causes it to dissociate from the DNA, thereby permitting gene transcription [1, 9, 13]. While not a direct therapeutic target for treating human disease, LacI is a critical tool in biotechnology and synthetic biology [3, 11]. It is widely used to create inducible gene expression systems in both prokaryotic and eukaryotic cells, facilitating the large-scale production of recombinant proteins and the development of sophisticated gene circuits for advanced therapies such as CAR-T cell engineering [6, 7, 11, 13].

Other names
Lac repressorLactose repressorLac operon repressorLacI protein
02

Mechanism of action

The LacI repressor functions as a homotetramer that binds to the operator DNA sequence (lacO) of the lactose operon, physically occluding RNA polymerase and inhibiting the transcription of genes required for lactose metabolism [1, 12, 13]. When an inducer molecule, such as the natural metabolite allolactose or the synthetic analog IPTG, binds to the core regulatory domain of LacI, it triggers an allosteric conformational change that significantly reduces the protein's affinity for the operator DNA. This dissociation allows RNA polymerase to access the promoter and initiate transcription of the operon [1, 9, 13].

03

Biological functions

Transcription regulationDNA bindingAllosteric regulationLactose metabolism regulation
04

Disease associations

Other
05

Safety considerations

Leaky basal expression (transcription occurring in the absence of inducer) [13]Potential immunogenicity of bacterial proteins if used in mammalian gene therapy applications [11]Toxicity of chemical inducers like IPTG at high concentrations in cellular environments [13]
06

Interacting drugs

Isopropyl β-D-1-thiogalactopyranoside (IPTG)

3 more in the full profile.

Beyond the preview

Go deeper on Lactose operon repressor (LacI) (LacI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactose operon repressor (LacI) (LacI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call